Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supplemental REACT Dosing in CKD
NCT05694169Phase 1Terminated
- Sponsor
- ProKidney
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilparencel in chronic kidney disease (CKD), diabetic kidney disease (DKD) and congenital anomalies of the kidney and urinary tract (CAKUT), sponsored by ProKidney. Primary endpoint: Primary Endpoint: Safety of Supplemental REACT Injections. Started Jul 2023; status: terminated.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)diabetic kidney disease (DKD)congenital anomalies of the kidney and urinary tract (CAKUT)
Beyond the preview
Go deeper on NCT05694169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694169.